

NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy

Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB ("NextCell" or the "Company"), will present the latest developments in the company at Redeye.

The presentation is live broadcasted and can be followed at [Redeye Theme: Regenerative Medicine/Cell Therapy - Redeye www.redeye.se/events/966283/redeye-theme-cell-therapy](https://www.redeye.se/events/966283/redeye-theme-cell-therapy) where the replay and the presentations will be available afterwards.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 0+46 8-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

For information about Cellaviva, please contact:

Sofie Falk Jansson, Head of Cellaviva
Tel: 08-735 2010
E-mail: info@cellaviva.se
Website: www.cellaviva.se

Facebook: <https://www.facebook.com/cellavivasverige>

Twitter: <https://www.instagram.com/cellaviva/>

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada.

Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva, Scandinavia's largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.